JP2022549328A - 細胞外小胞組成物 - Google Patents

細胞外小胞組成物 Download PDF

Info

Publication number
JP2022549328A
JP2022549328A JP2022518957A JP2022518957A JP2022549328A JP 2022549328 A JP2022549328 A JP 2022549328A JP 2022518957 A JP2022518957 A JP 2022518957A JP 2022518957 A JP2022518957 A JP 2022518957A JP 2022549328 A JP2022549328 A JP 2022549328A
Authority
JP
Japan
Prior art keywords
composition
concentration
aspects
phosphate
potassium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549328A5 (enExample
Inventor
コンリン オニール，
レイモンド ブルドー，
レーン ハリソン，
マイク ドハーティ，
アーロン ノイス，
Original Assignee
コディアック バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コディアック バイオサイエンシーズ， インコーポレイテッド filed Critical コディアック バイオサイエンシーズ， インコーポレイテッド
Publication of JP2022549328A publication Critical patent/JP2022549328A/ja
Publication of JP2022549328A5 publication Critical patent/JP2022549328A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022518957A 2019-09-25 2020-09-25 細胞外小胞組成物 Pending JP2022549328A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906018P 2019-09-25 2019-09-25
US62/906,018 2019-09-25
US201962906485P 2019-09-26 2019-09-26
US62/906,485 2019-09-26
PCT/US2020/052935 WO2021062317A1 (en) 2019-09-25 2020-09-25 Extracellular vesicle compositions

Publications (2)

Publication Number Publication Date
JP2022549328A true JP2022549328A (ja) 2022-11-24
JP2022549328A5 JP2022549328A5 (enExample) 2024-12-06

Family

ID=72840646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518957A Pending JP2022549328A (ja) 2019-09-25 2020-09-25 細胞外小胞組成物

Country Status (11)

Country Link
US (1) US20240099973A1 (enExample)
EP (1) EP4034081A1 (enExample)
JP (1) JP2022549328A (enExample)
KR (1) KR20220092654A (enExample)
CN (1) CN114727947A (enExample)
AU (1) AU2020355240A1 (enExample)
BR (1) BR112022005614A2 (enExample)
CA (1) CA3152478A1 (enExample)
IL (1) IL291690A (enExample)
MX (1) MX2022003570A (enExample)
WO (1) WO2021062317A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024114631A (ja) * 2023-02-10 2024-08-23 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4196144A1 (en) 2020-08-17 2023-06-21 Codiak BioSciences, Inc. Methods of treating cancer
US11931458B2 (en) 2021-01-11 2024-03-19 Babak Ghalili Exosome systems, products and methods
KR20230166101A (ko) * 2021-04-01 2023-12-06 론자 세일즈 아게 세포외 소포 조성물
AR128774A1 (es) * 2022-03-18 2024-06-12 Merck Patent Gmbh Métodos y composiciones para purificar pequeñas vesículas extracelulares
WO2023195976A1 (en) * 2022-04-05 2023-10-12 Babak Ghalili Exosome systems, products and methods
US20250382613A1 (en) * 2022-06-30 2025-12-18 Lonza Sales Ag Methods of using extracellular vesicle-aso targeting stat6
CN115282065B (zh) * 2022-08-11 2024-03-15 顾帅 一种含间充质干细胞外泌体的冻干粉及其制备方法和应用
WO2024206778A1 (en) * 2023-03-30 2024-10-03 Exoone Bio. Co., Ltd. Radiolabeled exosome and method and kit for preparing same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018070939A1 (en) * 2016-10-12 2018-04-19 Agency For Science, Technology And Research Method for lyophilising an exosome
WO2019040920A1 (en) * 2017-08-25 2019-02-28 Codiak Biosciences, Inc. PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
US20190175506A1 (en) * 2017-11-17 2019-06-13 Codiak Biosciences, Inc. Loading of Extracellular Vesicles through Imparting of Mechanical Shear
US20190202892A1 (en) * 2017-12-28 2019-07-04 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
WO2019157535A1 (en) * 2018-02-12 2019-08-15 Codiak Biosciences, Inc. Methods and compositions for macrophage polarization
WO2019155060A1 (en) * 2018-02-09 2019-08-15 Evox Therapeutics Ltd Compositions for extracellular vesicle storage and formulation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
WO2009088401A2 (en) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
MX2012004247A (es) * 2009-10-06 2012-06-25 Angiochem Inc Composiciones y metodos para el transporte de agentes terapeuticos.
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
ES2982836T3 (es) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
ES2764178T3 (es) 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
UY36969A (es) 2015-10-28 2017-05-31 Novartis Ag Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
SG11201804117XA (en) * 2015-11-18 2018-06-28 Univ Georgia Neural cell extracellular vessicles
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
AU2017368050A1 (en) * 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
WO2019099942A1 (en) 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of engineered exosomes and methods of loading luminal exosomes payloads
WO2019183578A1 (en) * 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
CN113286603B (zh) 2018-11-16 2025-07-22 隆萨销售股份公司 工程化的细胞外囊泡及其用途
US12233356B2 (en) * 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018070939A1 (en) * 2016-10-12 2018-04-19 Agency For Science, Technology And Research Method for lyophilising an exosome
WO2019040920A1 (en) * 2017-08-25 2019-02-28 Codiak Biosciences, Inc. PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
US20190175506A1 (en) * 2017-11-17 2019-06-13 Codiak Biosciences, Inc. Loading of Extracellular Vesicles through Imparting of Mechanical Shear
US20190202892A1 (en) * 2017-12-28 2019-07-04 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
WO2019155060A1 (en) * 2018-02-09 2019-08-15 Evox Therapeutics Ltd Compositions for extracellular vesicle storage and formulation
WO2019157535A1 (en) * 2018-02-12 2019-08-15 Codiak Biosciences, Inc. Methods and compositions for macrophage polarization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
""Phosphate-buffered saline"", WIKIPEDIAのインターネットアーカイブ [ONLINE], JPN6024033992, 30 March 2019 (2019-03-30), ISSN: 0005538989 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024114631A (ja) * 2023-02-10 2024-08-23 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液
JP7730003B2 (ja) 2023-02-10 2025-08-27 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液

Also Published As

Publication number Publication date
IL291690A (en) 2022-05-01
BR112022005614A2 (pt) 2022-07-12
CN114727947A (zh) 2022-07-08
KR20220092654A (ko) 2022-07-01
WO2021062317A1 (en) 2021-04-01
MX2022003570A (es) 2022-07-11
EP4034081A1 (en) 2022-08-03
AU2020355240A1 (en) 2022-04-21
CA3152478A1 (en) 2021-04-01
US20240099973A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US20240099973A1 (en) Extracellular vesicle compositions
ES2907967T3 (es) Vesículas extracelulares modificadas y sus usos
US12090235B2 (en) Preparation of lipid nanoparticles and methods of administration thereof
US20230364024A1 (en) Stabilized formulations of lipid nanoparticles
JP7635131B2 (ja) 脂質ナノ粒子の調製方法
TW202100164A (zh) 用於疫苗遞送之細胞外囊泡
JP7566629B2 (ja) ランゲリン＋細胞ターゲティング
TW202024120A (zh) 靶向樹突狀細胞之胞外囊泡及其用途
US20240082389A1 (en) Methods of producing extracellular vesicles
IL291786A (en) Interleukin 10 conjugates and their use
Zhao et al. Cyclic dinucleotide self-assembled nanoparticles as a carrier-free delivery platform for STING-mediated cancer immunotherapy
TW202345870A (zh) 具有延長半衰期之信使核糖核酸
WO2025026866A1 (en) Rna therapeutics with reduced toxicity
US20250382613A1 (en) Methods of using extracellular vesicle-aso targeting stat6
US20240209368A1 (en) Extracellular vesicle compositions
HK40118713A (zh) 使用靶向stat6的细胞外囊泡-aso的方法
CN120500355A (zh) 包含生物活性分子和细胞穿透肽可裂解接头的细胞外囊泡
HK40130942A (zh) 包含生物活性分子和细胞穿透肽可裂解接头的细胞外囊泡
HK40032716A (en) Engineered extracellular vesicles and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230921

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250819